Risk factors for placental human papillomavirus infection.
predictors
pregnancy
risk factors
Journal
Sexually transmitted infections
ISSN: 1472-3263
Titre abrégé: Sex Transm Infect
Pays: England
ID NLM: 9805554
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
10
06
2021
accepted:
06
02
2022
pubmed:
6
3
2022
medline:
22
11
2022
entrez:
5
3
2022
Statut:
ppublish
Résumé
Human papillomavirus (HPV) has been associated with adverse pregnancy outcomes but placental HPV infection has been rarely studied. The objective was to determine the proportion of HPV-positive placentas and the associated risk factors among HPV-positive women during pregnancy. We analysed data from pregnant women enrolled in HERITAGE cohort study between 2010 and 2016 with positive vaginal HPV infection during the first trimester of pregnancy (n=354). Placental swabs and biopsies were collected. HPV genotyping was performed using Linear Array. The predictors of placental HPV detection were identified by generalised estimating equations models. HPV was detected in 78 placentas (22.0%) (one among 96 caesarean sections and 77 among 258 vaginal deliveries). Overall, 91% of HPV-positive placentas were positive for a genotype that was detected in vaginal samples during pregnancy. Among women who delivered vaginally, abnormal cytology (adjusted OR (aOR) 1.78 (95% CI 1.02 to 3.10)), other genitourinary infection (aOR 2.41 (95% CI 1.31 to 4.44)), presence of multiple HPV genotypes in the first trimester (aOR 2.69 (95% CI 1.76 to 4.12)) and persistence of high-risk HPV infections during pregnancy (HPV-16/18: aOR 3.94 (95% CI 2.06 to 7.55) and other than HPV-16/18: aOR 2.06 (95% CI 1.05 to 4.02)) were independently associated with placental HPV. HPV was frequently detected in the placenta of women who delivered vaginally and may be associated with host immune response characteristics.
Identifiants
pubmed: 35246478
pii: sextrans-2021-055172
doi: 10.1136/sextrans-2021-055172
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
575-581Subventions
Organisme : CIHR
ID : MOP-93564
Pays : Canada
Organisme : CIHR
ID : MOP-136833
Pays : Canada
Investigateurs
Helen Trottier
(H)
Marie-Hélène Mayrand
(MH)
François Coutlée
(F)
Patricia Monnier
(P)
William Fraser
(W)
Ana Maria Carceller
(AM)
Paul Brassard
(P)
Jacques Lacroix
(J)
Diane Francoeur
(D)
Marie-Josée Bédard
(MJ)
Isabelle Girard
(I)
François Audibert
(F)
Louise Laporte
(L)
Joseph Niyibizi
(J)
Monica Zahreddine
(M)
Informations de copyright
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: FC has received grants to evaluate HPV detection tests through his institution from Becton-Dickson and Roche Molecular systems. HT has received occasional lecture fees from Merck and unrestricted grants form ViiV Healthcare. All other coauthors have no conflict of interests.